桑葚样化生对子宫内膜增生及G1子宫内膜样腺癌保留生育功能治疗的临床意义
MM组完全缓解率更低、中位完全缓解时间更长,持续出现MM及治疗后出现MM是延迟完全缓解的独立危险因素,宫腔镜下砂砾样改变可能是MM的特征性表现。
要点
- 合并MM者完全缓解率更低、中位完全缓解时间更长。
- 持续出现MM及治疗后出现MM是延迟完全缓解的独立危险因素。
- 宫腔镜下砂砾样改变可能是MM的特征性表现。
核心结论
- 合并MM的患者较未合并MM的患者保留生育功能治疗结果差。
- 持续出现MM以及治疗后出现MM是年轻子宫内膜增生及子宫内膜样腺癌G1患者保留生育功能治疗效果欠佳的危险因素。
- 宫腔镜下子宫内膜砂砾样改变可能是MM的特征性表现。
研究设计与样本
- 回顾性收集2018年1月至2022年11月天津医科大学总医院诊断为子宫内膜增生或子宫内膜样腺癌G1、年龄<40岁并接受以孕激素为基础保留生育功能治疗患者的临床资料。
- 按病理是否合并MM分为MM组37例和非MM组63例。
- MM组进一步分为MM-Bef组10例、MM-Sus组14例和MM-Aft组13例。
- 对影响治疗结局的相关因素进行单因素及多因素Cox回归分析。
主要发现
- MM组合并PCOS比例高于非MM组[51%(19/37)vs 27%(17/63),P=0.014]。
- MM组完全缓解率低于非MM组[73%(27/37)vs 95%(60/63),P=0.006]。
- MM组中位完全缓解时间长于非MM组(6.0 vs 5.0个月,P=0.005)。
- 多因素分析显示MM-Sus(HR=0.355,95%CI:0.174~0.723;P=0.004)和MM-Aft(HR=0.314,95%CI:0.145~0.681;P=0.003)均为完全缓解率低的独立危险因素。
- MM组宫腔镜下砂砾样改变发生率高于非MM组[18%(14/76)vs 2%(2/131),P<0.001]。
临床怎么用
- 对年轻子宫内膜增生或子宫内膜样腺癌G1保留生育功能治疗患者应关注病理是否合并MM。
- 对持续出现MM或治疗后出现MM者应警惕完全缓解延迟。
- 宫腔镜下发现砂砾样改变时应注意MM可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the clinical significance of morular metaplasia (MM) in fertility-preserving treatment for young patients with endometrial hyperplasia and grade 1 endometrial endometrioid carcinoma. Methods: Clinical data was retrospectively collected from patients diagnosed with endometrial hyperplasia or grade 1 endometrial endometrioid carcinoma under 40 years old who underwent progestin-based fertility-sparing treatmentat in Tianjin Medical University General Hospital between January 2018 and November 2022.Patients were divided into the MM group (37 cases) and the non-MM group (63 cases) based on pathological findings. Clinical characteristics, hysteroscopic features, treatment efficacy and fertility outcomes were compared between the two groups. The MM group was further stratified into three subgroups based on the timing of MM occurrence:(1) MM-Bef group (n=10): MM was present in the initial endometrial curettage or hysteroscopic biopsy pathology before fertility-sparing treatment and disappeared after treatment; (2) MM-Sus group (n=14): MM persisted consistently before and after therapy;(3) MM-Aft group (n=13): MM was absent before therapy but appeared after treatment. The risk factors which had impact on the treatment outcomes of the patients were analyzed using univariate and multivariate Cox regression analysis. Results: The rate of polycystic ovary syndrome were higher in the MM group than the non-MM group [51% (19/37) vs 27% (17/63), P=0.014]. The complete response (CR) rate was significantly lower in the MM group than in the non-MM group [73% (27/37) vs 95% (60/63), P=0.006], and the median time to CR was significantly longer in the MM group (6.0 vs 5.0 months, P=0.005).Multivariate analysis identified that MM-Sus (HR=0.355, 95%CI:0.174-0.723; P=0.004) and MM-Aft (HR=0.314, 95%CI:0.145-0.681; P=0.003) were independent risk factors for delayed CR in fertility-sparing treatment. The patients in the MM group and non-MM group underwent hysteroscopic biopsy for 76 and 131 times. "Gravel-like change" was a more frequent hysteroscopic manifestation in the MM group than that in the non-MM group [18% (14/76) vs 2% (2/131), P<0.001]. Conclusions: Patients in the MM group have poorer treatment outcomes than patients in the non-MM group. MM-Sus and MM-Aft are risk factors for fertility-preserving treatment in young patients with endometrial hyperplasia or grade 1 endometrial endometrioid carcinoma. "Gravel-like change" is the characteristic hysteroscopic manifestations of MM. 目的: 评估桑葚样化生(MM)在年轻子宫内膜增生及子宫内膜样腺癌G1患者保留生育功能治疗中的临床意义。 方法: 回顾性收集2018年1月至2022年11月在天津医科大学总医院诊断为子宫内膜增生或子宫内膜样腺癌G1,年龄<40岁并且接受以孕激素为基础的保留生育功能治疗患者的临床资料,根据病理检查结果是否合并MM将患者分为MM组(37例)和非MM组(63例),对患者的临床特征、宫腔镜特征、治疗效果和生育结局进行比较分析。根据MM出现时间进一步将MM组患者分为三个亚组:(1)接受保留生育功能治疗前诊断性刮宫或宫腔镜活检病理出现MM,治疗后MM消失(MM-Bef组)10例;(2)保留生育功能治疗前后持续出现MM(MM-Sus组)14例;(3)保留生育功能治疗前未出现MM,治疗后出现MM(MM-Aft组)13例。对影响子宫内膜增生和子宫内膜样腺癌G1患者治疗结局的相关因素进行单因素及多因素回归分析。 结果: MM组合并PCOS的患者比例高于非MM组[分别为51%(19/37)、27%(17/63),P=0.014]。MM组的完全缓解(CR)率低于非MM组[分别为73%(27/37)、95%(60/63),P=0.006];MM组的中位CR时间高于非MM组(分别为6.0、5.0个月,P=0.005)。多因素分析显示,MM-Sus(HR=0.355,95%CI为0.174~0.723;P=0.004)和MM-Aft(HR=0.314,95%CI为0.145~0.681;P=0.003)均为保留生育功能治疗中CR率低的独立危险因素。MM组患者共行宫腔镜检查76例次,非MM组131例次。MM组患者宫腔镜下病灶砂砾样改变发生率高于非MM组[分别为18%(14/76)、2%(2/131),P<0.001]。 结论: 合并MM的患者较未合并MM的患者保留生育功能治疗结果差,持续出现MM以及治疗后出现MM是年轻子宫内膜增生及子宫内膜样腺癌G1患者保留生育功能治疗的效果欠佳危险因素。宫腔镜下子宫内膜砂砾样改变可能是MM的宫腔镜特征性表现。.
引用
- Zhao SS, Zhang DC, Li T, et al. [Clinical implications of morular metaplasia in fertility-preserving treatment for endometrial hyperplasia and grade 1 endometrial endometrioid carcinoma patients]. Zhonghua Fu Chan Ke Za Zhi. 2025. PMID: 41320653. doi:10.3760/cma.j.cn112141-20250621-00285
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。